Holen Sie sich die Stockscreener-App
6.745
3.45%
0.225
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - PR Newswire
Capricor Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
Is Capricor Therapeutics Inc. a good long term investmentBreakthrough stock performance - Autocar Professional
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsCAPR - Business Wire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - PR Newswire
Behind Capricor Therapeutics Inc’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
What analysts say about Capricor Therapeutics Inc. stockTriple-digit growth rates - jammulinksnews.com
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 15% loss last week hit both individual investors who own 47% as well as institutions - simplywall.st
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
What drives Capricor Therapeutics Inc. stock priceBreakout portfolio performance - Autocar Professional
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Securities Fraud and Market Volatility in Biotech: Lessons from Capricor's Downfall - AInvest
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The Globe and Mail
Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025Capricor Therapeutics, Inc. (CAPR) - TradingView
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Important Notice to Long-Term Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR); Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigatin - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 15, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shareholders of Class Action Lawsuit and September 15, 2025 Deadline - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - StreetInsider
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Capricor Therapeutics, Inc.September 15, 2025 Deadline - ACCESS Newswire
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: - GlobeNewswire
Investor Sues Biotech Capricor After Product's FDA Denial - Law360
Levi & Korsinsky Urges Capricor Therapeutics, Inc. (CAPR) Shareholders to Act Before Lead Plaintiff Deadline September 15, 2025 - ACCESS Newswire
Capricor Investor Sues After Disappointing FDA Return on Therapy - Bloomberg Law News
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - TradingView
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Will Capricor Therapeutics Inc. stock split in the near futureInvestor Favorite Picks - Newser
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewswire
CAPR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. Investors - TradingView
Capricor’s Trial Data Deception Triggers Major Lawsuit - TipRanks
What analysts say about Capricor Therapeutics Inc. stock outlookPrecision Entry Strategy - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent
Shareholders Filed a Lawsuit Against Capricor for Misleading Investors About FDA Approval - TradingView
Capricor Therapeutics ($CAPR) Regulatory Misrepresentations and Stock Collapse Case - TradingView
BREAKING: Capricor Therapeutics Sued For Securities Fraud; - GlobeNewswire
September 15, 2025 Deadline Approaching: Join Class Action Against Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky - ACCESS Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action - GlobeNewswire
4.56%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):